Skip to content
10-Q

Quarterly Report

IN8BIO, INC. INAB

0001193125-26-212135

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 9.85M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.47M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 2.58M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.95M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.12M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $22.16M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $27.31M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $12.16M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $11.39M
Stockholders Equity Q1 2026 · Mar 31, 2026 $22.78M
Stockholders Equity Q1 2026 · Dec 31, 2025 $27.56M
Stockholders Equity Q1 2026 · Mar 31, 2025 $13.88M
Stockholders Equity Q1 2026 · Dec 31, 2024 $14.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.16M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.16M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.48M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.72M
Current Assets Q1 2026 · Mar 31, 2026 $22.66M
Current Assets Q1 2026 · Dec 31, 2025 $27.88M
Total Assets Q1 2026 · Mar 31, 2026 $26.27M
Total Assets Q1 2026 · Dec 31, 2025 $32.28M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.26
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.16
Eps Basic Q1 2026 · Mar 31, 2026 −$0.26
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.16
Sga Expense Q1 2026 · Mar 31, 2026 $2.65M
Sga Expense Q1 2026 · Mar 31, 2025 $2.69M
Rd Expense Q1 2026 · Mar 31, 2026 $2.61M
Rd Expense Q1 2026 · Mar 31, 2025 $2.97M
Net Income Q1 2026 · Mar 31, 2026 −$5.09M
Net Income Q1 2026 · Mar 31, 2025 −$5.55M
Operating Income Q1 2026 · Mar 31, 2026 −$5.09M
Operating Income Q1 2026 · Mar 31, 2025 −$5.55M